Drug Overview
Stivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients.
It is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor), stromal, and oncogenic (KIT, RET, and BRAF) kinases. It is currently also approved for the third-line treatment of metastatic colorectal cancer and the second-line treatment of gastrointestinal stromal tumor.
Stivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients.
It is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor), stromal, and oncogenic (KIT, RET, and BRAF) kinases. It is currently also approved for the third-line treatment of metastatic colorectal cancer and the second-line treatment of gastrointestinal stromal tumor.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES